Listen
CYRAMZA (ramucirumab), monoclonal antibody
ONCOLOGY - New indication
Opinions on drugs -
Posted on
Mar 29 2017
Reason for request
Extension of indication
Moderate clinical benefit in combination with FOLFIRI chemotherapy (irinotecan, folinic acid and 5-fluorouracil) in the treatment of metastatic colorectal cancer.
- CYRAMZA has Marketing Authorisation in combination with FOLFIRI chemotherapy (irinotecan, folinic acid and 5-fluorouracil) in the treatment of metastatic colorectal cancer (mCRC) in which the illness progressed during or after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine.
- A modest effect of CYRAMZA on overall survival and progression-free survival has been demonstrated versus placebo, but no improvement in quality of life has been demonstrated.
- No comparative data versus the available targeted therapies (bevacizumab and cetuximab) are available.
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
Documents
English version
Contact Us
Évaluation des médicaments
